Moreover, the use of PSMA-PET in restaging PCa patients lead to a change in clinical management in approximately 50% of cases [8,9,10], despite the fact that evidence of a survival benefit of treatment changes are scarce. The gene discussed is FOLH1; the disease is posterior cortical atrophy.